trending Market Intelligence /marketintelligence/en/news-insights/trending/0hoc5a1zno8i-ube_zrxsa2 content esgSubNav
In This List

Aevi Genomic director to retire

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Aevi Genomic director to retire

Wilbur Gantz will not stand for re-election to the board of Aevi Genomic Medicine Inc. at the 2018 annual stockholders meeting.

Gantz, who informed the company March 19 that he plans to retire, will continue to serve until his current term expires at the annual meeting.

Gantz has been a director of the Pennsylvania-based clinical stage biopharmaceutical company since October 2013.